A method of treating depression using orexin-2 receptor antagonists.

Abstract

To provide a treatment method effective for depression. 【Solution means】A method for treating a subject suffering from or diagnosed with depression, comprising administering to a subject requiring such treatment an effective amount of a compound of formula (I): JPEG2026097812000022.jpg56128 (wherein R 1 is C 1~4 alkyl, R 2 is C 1~4 alkyl, R 3 is H or halogen, and R 4 is H or C 1~4 alkoxy), or a pharmaceutically acceptable salt or hydrate thereof.

Claims

1. A method for treating a person suffering from depression or diagnosed with depression, For subjects requiring such treatment, an effective amount of the compound of formula (I): 【Chemistry 1】 (In the formula, R １ C １～４ It is alkyl, R ２ C １～４ It is alkyl, R ３ is H or halogen, R ４ is H or C １～４ (It is an alkoxy.) or administering a pharmaceutically acceptable salt or hydrate thereof, A method wherein the compound is administered before sleep.

2. Claim 1, the subject is not suffering from an insomnia disorder and has not been diagnosed with such an insomnia disorder. Methods used.

3. R ３ The method according to claim 1, wherein is a halogen.

4. R ３ The method according to claim 3, wherein R is fluorine.

5. R ４ The method according to claim 1, wherein H is

6. R ４ C １～４ The method according to claim 1, wherein the alkoxy is used.

7. R ４ The method according to claim 6, wherein is methoxy.

8. R ３ The method according to claim 1, wherein H is

9. R １ CH ３ The method according to claim 1.

10. R ２ CH ３ The method according to claim 1.

11. The aforementioned compound is 5-(4,6-dimethylpyrimidine-2-yl)-hexahydro-py [3,4-c]pyrrole-2-yl]-(2-fluoro-6-[1,2,3]tria) The claim is for zole-2-ylphenyl)-methanone or a pharmaceutically acceptable salt thereof. The method described in item 1.

12. The aforementioned compound is 5-(4,6-dimethylpyrimidine-2-yl)-hexahydro-py [3,4-c]pyrrole-2-yl]-(2-fluoro-6-[1,2,3]tria) The method according to claim 1, wherein the material is zole-2-ylphenyl)methanone.

13. The aforementioned compound is 5-(4,6-dimethylpyrimidine-2-yl)-hexahydro-py [3,4-c]pyrrole-2-yl]-(2-fluoro-6-[1,2,3]tria) The method according to claim 1, wherein the salt is zole-2-ylphenyl)methanone hydrochloride.

14. The aforementioned compound is (5-(4,6-dimethylpyrimidine-2-yl)hexahydropyrrolo [3,4-c]pyrrole-2(1H)-yl)(4-methoxy-2-(2H-1,2,3 -Triazole-2-yl)phenyl)methanone or a pharmaceutically acceptable salt thereof. The method according to claim 1.

15. The aforementioned compound is (5-(4,6-dimethylpyrimidine-2-yl)hexahydropyrrolo [3,4-c]pyrrole-2(1H)-yl)(4-methoxy-2-(2H-1,2,3 The method according to claim 1, wherein the substance is triazole-2-yl)phenyl)methanone.

16. The method according to claim 1, wherein the compound is administered at night.

17. The method according to claim 1, wherein the compound is administered daily.

18. The method according to claim 1, wherein the compound is administered orally.

19. The method according to claim 1, wherein the effective amount is about 10 to about 40 mg.

20. The aforementioned depression may be major depressive disorder, depression associated with bipolar disorder, or treatment-resistant depression. The method according to claim 1, including the method described in claim 1.

21. The method according to claim 20, wherein the depression is major depressive disorder.

22. The method according to claim 20, wherein the depression is treatment-resistant depression.

23. The method according to claim 1, further comprising administering a second antidepressant.

24. The second antidepressant is a selective serotonin reuptake inhibitor, serotonin, and norepinephrine. The method according to claim 23, wherein a narin reuptake inhibitor, or a combination thereof.

Images